Influence of autoimmune biomarkers on interstitial lung diseases: A tertiary referral center based case-control study

Philippe R. Bauer, Sanjay Kalra, Thomas Osborn, Jennifer St. Sauver, Andrew C. Hanson, Darrell R. Schroeder, Jay H Ryu

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: The benefit of routinely measuring autoimmune biomarkers to evaluate patients with interstitial lung disease (ILD) remains debated outside specific contexts such as connective tissue disease (CTD). This study aimed at evaluating the influence of biomarkers on outcome on patients with ILD in a case-control study at a tertiary referral center. We hypothesized that patients with positive autoimmune biomarkers have increased odds of developing ILD even in the absence of CTD. Methods: We reviewed the medical records of 3573 patients seen at the ILD clinic in Mayo Clinic Rochester between September 2001 and September 2006. We assessed their clinical course through June 25, 2013. We included patients with patterns of ILD most often associated with CTD (n=1256) while excluding patients with other known causes of ILD. Controls (n=2317) included cases seen at the ILD clinic without evidence of ILD. Results: We identified 930 (26%) cases of ILD alone, 124 (3%) CTD alone, 326 (9%) ILD combined with CTD, and 2193 (61%) with no ILD or CTD. Positive antinuclear antibodies (ANA), rheumatoid factor and aldolase were associated with ILD. After adjustment for age, gender, race, smoking history and CTD, ANA remained an independent risk factor for ILD (OR 1.70, 95% CI 1.33-2.17). Among patients with ILD, the presence of CTD but not biomarker alone was associated with a better survival. Conclusion: In this study, the presence of positive biomarkers was associated with increased odds of ILD, even in the absence of overt CTD, but was not associated with a better outcome.

Original languageEnglish (US)
JournalRespiratory Medicine
DOIs
StateAccepted/In press - Aug 20 2014

Fingerprint

Interstitial Lung Diseases
Tertiary Care Centers
Case-Control Studies
Biomarkers
Connective Tissue Diseases
Antinuclear Antibodies
Fructose-Bisphosphate Aldolase
Rheumatoid Factor
Medical Records

Keywords

  • Antinuclear antibodies
  • Biomarkers
  • Case-control study
  • Connective tissue disease
  • Interstitial lung disease

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

@article{dcb791a40a9b4f7da94ff9460d3a7754,
title = "Influence of autoimmune biomarkers on interstitial lung diseases: A tertiary referral center based case-control study",
abstract = "Background: The benefit of routinely measuring autoimmune biomarkers to evaluate patients with interstitial lung disease (ILD) remains debated outside specific contexts such as connective tissue disease (CTD). This study aimed at evaluating the influence of biomarkers on outcome on patients with ILD in a case-control study at a tertiary referral center. We hypothesized that patients with positive autoimmune biomarkers have increased odds of developing ILD even in the absence of CTD. Methods: We reviewed the medical records of 3573 patients seen at the ILD clinic in Mayo Clinic Rochester between September 2001 and September 2006. We assessed their clinical course through June 25, 2013. We included patients with patterns of ILD most often associated with CTD (n=1256) while excluding patients with other known causes of ILD. Controls (n=2317) included cases seen at the ILD clinic without evidence of ILD. Results: We identified 930 (26{\%}) cases of ILD alone, 124 (3{\%}) CTD alone, 326 (9{\%}) ILD combined with CTD, and 2193 (61{\%}) with no ILD or CTD. Positive antinuclear antibodies (ANA), rheumatoid factor and aldolase were associated with ILD. After adjustment for age, gender, race, smoking history and CTD, ANA remained an independent risk factor for ILD (OR 1.70, 95{\%} CI 1.33-2.17). Among patients with ILD, the presence of CTD but not biomarker alone was associated with a better survival. Conclusion: In this study, the presence of positive biomarkers was associated with increased odds of ILD, even in the absence of overt CTD, but was not associated with a better outcome.",
keywords = "Antinuclear antibodies, Biomarkers, Case-control study, Connective tissue disease, Interstitial lung disease",
author = "Bauer, {Philippe R.} and Sanjay Kalra and Thomas Osborn and {St. Sauver}, Jennifer and Hanson, {Andrew C.} and Schroeder, {Darrell R.} and Ryu, {Jay H}",
year = "2014",
month = "8",
day = "20",
doi = "10.1016/j.rmed.2015.01.011",
language = "English (US)",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Influence of autoimmune biomarkers on interstitial lung diseases

T2 - A tertiary referral center based case-control study

AU - Bauer, Philippe R.

AU - Kalra, Sanjay

AU - Osborn, Thomas

AU - St. Sauver, Jennifer

AU - Hanson, Andrew C.

AU - Schroeder, Darrell R.

AU - Ryu, Jay H

PY - 2014/8/20

Y1 - 2014/8/20

N2 - Background: The benefit of routinely measuring autoimmune biomarkers to evaluate patients with interstitial lung disease (ILD) remains debated outside specific contexts such as connective tissue disease (CTD). This study aimed at evaluating the influence of biomarkers on outcome on patients with ILD in a case-control study at a tertiary referral center. We hypothesized that patients with positive autoimmune biomarkers have increased odds of developing ILD even in the absence of CTD. Methods: We reviewed the medical records of 3573 patients seen at the ILD clinic in Mayo Clinic Rochester between September 2001 and September 2006. We assessed their clinical course through June 25, 2013. We included patients with patterns of ILD most often associated with CTD (n=1256) while excluding patients with other known causes of ILD. Controls (n=2317) included cases seen at the ILD clinic without evidence of ILD. Results: We identified 930 (26%) cases of ILD alone, 124 (3%) CTD alone, 326 (9%) ILD combined with CTD, and 2193 (61%) with no ILD or CTD. Positive antinuclear antibodies (ANA), rheumatoid factor and aldolase were associated with ILD. After adjustment for age, gender, race, smoking history and CTD, ANA remained an independent risk factor for ILD (OR 1.70, 95% CI 1.33-2.17). Among patients with ILD, the presence of CTD but not biomarker alone was associated with a better survival. Conclusion: In this study, the presence of positive biomarkers was associated with increased odds of ILD, even in the absence of overt CTD, but was not associated with a better outcome.

AB - Background: The benefit of routinely measuring autoimmune biomarkers to evaluate patients with interstitial lung disease (ILD) remains debated outside specific contexts such as connective tissue disease (CTD). This study aimed at evaluating the influence of biomarkers on outcome on patients with ILD in a case-control study at a tertiary referral center. We hypothesized that patients with positive autoimmune biomarkers have increased odds of developing ILD even in the absence of CTD. Methods: We reviewed the medical records of 3573 patients seen at the ILD clinic in Mayo Clinic Rochester between September 2001 and September 2006. We assessed their clinical course through June 25, 2013. We included patients with patterns of ILD most often associated with CTD (n=1256) while excluding patients with other known causes of ILD. Controls (n=2317) included cases seen at the ILD clinic without evidence of ILD. Results: We identified 930 (26%) cases of ILD alone, 124 (3%) CTD alone, 326 (9%) ILD combined with CTD, and 2193 (61%) with no ILD or CTD. Positive antinuclear antibodies (ANA), rheumatoid factor and aldolase were associated with ILD. After adjustment for age, gender, race, smoking history and CTD, ANA remained an independent risk factor for ILD (OR 1.70, 95% CI 1.33-2.17). Among patients with ILD, the presence of CTD but not biomarker alone was associated with a better survival. Conclusion: In this study, the presence of positive biomarkers was associated with increased odds of ILD, even in the absence of overt CTD, but was not associated with a better outcome.

KW - Antinuclear antibodies

KW - Biomarkers

KW - Case-control study

KW - Connective tissue disease

KW - Interstitial lung disease

UR - http://www.scopus.com/inward/record.url?scp=84922210488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922210488&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2015.01.011

DO - 10.1016/j.rmed.2015.01.011

M3 - Article

C2 - 25670028

AN - SCOPUS:84933181207

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

ER -